Merial Limited v Intervet International B.V

Link copied
Case Copied 51 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Merial Limited v Intervet International B.V. [2016] APO 39

Patent Application:                   2006289102

Title:PCV-2 vaccine

Patent Applicant:  Intervet International B.V.

Opponent:  Merial Limited

Delegate:  Dr B. Akhurst

Decision Date:  27 June 2016

Hearing Date:  6 April 2016

Catchwords:  PATENTS – section 59 opposition to grant of a patent – manner of manufacture – a feature of the claims is not obvious of the face of the specification – manner of manufacture ground not established – novelty – the prior art documents relied on do not provide clear and unmistakable directions to the combination of features in the claims – lack of novelty not established – inventive step – the person skilled in the art would directly be led as a matter of course to try the Blanchard PCV-2 ORF-2 protein in doses encompassed by the opposed claims with a reasonable expectation that it might well solve the problem – the claims lack an inventive step – useful – lack of utility not established – fair basis – not established

Representation:  Patent attorney for the applicant: David Myers of Spruson & Ferguson.

Counsel for the opponent:  Jon Gottshall.

Patent attorney for the opponent: Jane Hutchison and Jenny Petering of FB Rice. 

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2006289102

Title:PCV-2 vaccine

Patent Applicant:  Intervet International B.V.

Date of Decision:  27 June 2016

DECISION

The opposition is successful.  Claims 1-6 and 8-11 lack an inventive step.

Intervet International B.V. has 2 months from the date of this decision to propose amendments to the claims.

I make no award of costs.

REASONS FOR DECISION

Background

  1. Intervet International B.V. (Intervet) filed patent application 2006289102 via the PCT on 8 September 2006, claiming priority from application EP 05108299.8 filed on 9 September 2005.  Following examination, acceptance of the application was advertised on 15 December 2011. 

  2. Merial Limited (Merial) filed a notice of opposition on 15 March 2012 and a statement of grounds and particulars (SGP) on 15 June 2012.  After extensions of time were granted at each stage, evidence in support was completed on 15 February 2013 and evidence in answer on 16 June 2014.  Evidence in reply was completed on 15 September 2014.  On 23 March 2015, Merial filed requests to amend the SGP and to file further evidence, accompanied by the evidence.  The amendment request and the further evidence were allowed on 16 April 2015 and 9 June 2015, respectively.  Intervet filed responding evidence on 10 August 2015.

  3. The matter was heard on 6 April 2016 in Canberra. 

    The Evidence

  4. Evidence in support consisted of declarations by:

    • Christopher Chase dated 13 November 2012 (Chase#1) with exhibits CC-1 to CC-8
    • Richard Bevan dated 13 February 2013 (Bevan#1) with exhibits RB-1 and RB-2
  5. Evidence in answer consisted of a declaration by:

    • Mark A. O’Dea (O’Dea#1) dated 16 June 2014 with exhibits MOD-1 to MOD-12
  6. Evidence in reply consisted of declarations by:

    • Christopher Chase dated 11 September 2014 (Chase#2
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merial Limited v Intervet International B.V and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] APO 39
Decision Date

CaseChat Overview and Summary

This case involved an opposition to the grant of patent application 2006289102 for a PCV-2 vaccine. The applicant, Intervet International B.V., was opposed by Merial Limited, which argued that the claims lacked novelty, inventive step, utility and fair basis. The Delegate of the Commissioner of Patents, Dr Barbara Akhurst, found that the opposition was successful in respect of inventive step, but unsuccessful in respect of novelty, utility and fair basis. The Delegate found that claims 1-6 and 8-11 lacked an inventive step in light of the prior art disclosure in Blanchard et al. (2003) Vaccine 21: 4565-4575. The Delegate found that Merial had not established that the claims lacked novelty, utility or fair basis. The Delegate allowed Intervet two months to propose amendments to the claims. The Delegate made no award of costs.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.